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Metformin activates both PRKA and SIRT1. Furthermore, autophagy is induced by either the PRKA-MTOR-ULK1 or
SIRT1-FOXO signaling pathways. We aimed to elucidate the mechanism by which metformin alleviates hepatosteatosis
by examining the molecular interplay between SIRT1, PRKA, and autophagy. ob/ob mice were divided into 3 groups:
one with ad libitum feeding of a standard chow diet, one with 300 mg/kg intraperitoneal metformin injections, and one
with 3 g/d caloric restriction (CR) for a period of 4 wk. Primary hepatocytes or HepG2 cells were treated with oleic acid
(OA) plus high glucose in the absence or presence of metformin. Both CR and metformin signiﬁcantly improved body
weight and glucose homeostasis, along with hepatic steatosis, in ob/ob mice. Furthermore, CR and metformin both
upregulated SIRT1 expression and also stimulated autophagy induction and ﬂux in vivo. Metformin also prevented OA
with high glucose-induced suppression of both SIRT1 expression and SIRT1-dependent activation of autophagy
machinery, thereby alleviating intracellular lipid accumulation in vitro. Interestingly, metformin treatment upregulated
SIRT1 expression and activated PRKA even after siRNA-mediated knockdown of PRKAA1/2 and SIRT1, respectively. Taken
together, these results suggest that metformin alleviates hepatic steatosis through PRKA-independent, SIRT1-mediated
effects on the autophagy machinery.
Introduction
Efforts for treating nonalcoholic fatty liver disease (NAFLD)
have traditionally focused on burning excess energy and
unloading caloric burdens, on either the individual or cellular
level. To achieve the aims of increasing energy expenditure and
mimicking caloric restriction (CR) in the treatment of meta-
bolic disease, a thorough understanding of the molecular
machinery involved in these processes is required. Understand-
ing how this molecular machinery is dysregulated or dysfunc-
tional in NAFLD is also crucial. Although metformin is the
first-line antidiabetic drug, particularly for overweight and
obese people and those with normal kidney function, the idea
that metformin exerts pleiotropic effects via novel mechanisms
of action is now gaining popularity.1,2 In this regard, the mech-
anism by which metformin alleviates hepatosteatosis and the
effects of metformin on autophagy are 2 current areas of debate
and investigation.
The traditional pathways of autophagy induction are either
through PRKA (protein kinase, AMP-activated)-MTOR-ULK1
mediated signaling, activated by an increase in the AMP/ATP
ratio, or the sirtuin class of histone/protein deacetylases (SIRT1)-
FOXO pathway, activated by increased NADC.3,4 In addition,
metformin is well-established to activate both PRKA and the
NADC-dependent deacetylase SIRT1.5 Based on these reports,
we aimed to elucidate the mechanism by which metformin allevi-
ates NAFLD by investigating the molecular interplay between
PRKA, SIRT1, and autophagy.
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Results
Metformin and caloric restriction decrease body weight
and blood glucose in ob/ob mice
To confirm the reported beneficial metabolic phenotypes of
metformin treatment and CR in vivo, body weight and gluco-
metabolic parameters were assessed in C57bl/6j control and ob/
ob mice through weekly fasted blood glucose measurements and
intraperitoneal glucose tolerance tests (IPGTTs). The ob/ob
mouse, an animal model of obesity and type 2 diabetes, eats
excessively and expresses mutation in the gene encoding LEP/lep-
tin, which is important in the control of appetite. Despite
increased levels of insulin, ob/ob mice develop high blood glu-
cose.6 Whole body weights of ob/ob mice treated with 3 g/d CR
(p < 0.001 at 1, 2, 3, and 4 wk) and 300 mg/kg metformin (p <
0.01 at 1 and 2 wk, p < 0.05 at 4 wk) were significantly lower
than those fed ad libitum (Fig. 1A).
Except for ob/ob mice treated with CR
(all p < 0.001), food intakes were not
different among ob/ob mice (Fig. 1B).
As shown in Fig. 1C, blood glucose
levels in the fasting condition were sig-
nificantly decreased throughout the
entire experiment by metformin treat-
ment (p < 0.05 at 1 wk; p < 0.01 at 2,
3 wk; p < 0.001 at 4 wk) and CR
treatment (p < 0.001) compared with
ad libitum-fed mice, whose blood glu-
cose levels ranged from 300 to
400 mg/dL at 2 wk post-ad libitum.
To investigate the effect of metformin
treatment and CR on glucose toler-
ance, we performed 2 g/kg body
weight IPGTTs at 3 wk (Fig. 1D).
Compared to ad libitum-fed mice, tol-
erances to glucose loading were signifi-
cantly improved in CR-treated mice at
all-time points tested (p < 0.001) and
in metformin-treated mice at 60, 90,
and 120 min (p < 0.05, p < 0.01, and
p < 0.01, respectively).
Metformin and caloric restriction
alleviate liver dysfunction and hepatic
lipid accumulation in ob/ob mice
To examine whether metformin
and CR alleviated hepatic fat accumu-
lation in vivo, serum levels for total
cholesterol (T-CHO), GOT1/AST
(glutamic-oxaloacetic transaminase 1,
soluble), and GPT/ALT, (glutamic-
pyruvate transaminase [alanine amino-
transferase]), as well as triglyceride
(TG) contents and hepatic histology
were evaluated in C57bl/6j control
and ob/ob mice. Serum levels of
T-CHO were significantly reduced in both the CR- (97.3 §
10.4, p < 0.01) and metformin-treated groups (101.9§ 8.9, p <
0.01) compared to the ad libitum-fed group (122.8§ 15.6 mg/
dL, Fig. 2A). The elevated GOT1 and GPT serum levels of the
ad libitum-fed group (37.74§ 5.49 and 33.53§ 5.15, respec-
tively) were significantly lowered by treatment with CR (19.54§
1.28 and 17.09§ 3.26, both p < 0.05) and metformin (21.95§
3.07 and 18.74§ 3.82, both p < 0.05, respectively; Fig. 2B and
C). As shown in Figure 2D, liver weights adjusted by body
weights in the CR- (1.53§ 0.15 g, p < 0.05) and metformin-
treated groups (2.20§ 0.16 g, p < 0.001) were significantly
lower than those in the ad libitum-fed group (2.88§ 0.35 g).
Compared to the ad libitum-fed mice (3.89§ 0.49 TG/protein
nm/mg), CR- (0.85§ 0.06, p < 0.001) and metformin-treated
mice (2.13§ 0.70, p < 0.05) showed a significant decrease in
hepatic TG contents as assessed by a Quantification Colorimetric
Figure 1. Metabolic effects of metformin and caloric restriction on ob/ob mice. The effects of metfor-
min and CR on body weight (A), food intake (B), and blood glucose (C) in the 8-wk-old C57bl/6j control
() and ob/ob mice were evaluated. The latter mice were classiﬁed into 3 groups: ad libitum feeding
of chow diets (~), 300 mg/kg intraperitoneal metformin (4), and 3 g/d CR (Ø). During a 4-wk treat-
ment course of either metformin or CR, body weight signiﬁcantly decreased compared to ad libitum-
fed ob/ob mice (A). Due to the protocol of this study, food intake was only reduced in calorie-restricted
mice. Blood glucose levels were signiﬁcantly decreased throughout the entire 4 wk in ob/ob mice
treated either with metformin or CR, compared to ad libitum-fed ob/ob mice (C). At 3 wk, glucose toler-
ance tests were performed after an intraperitoneal injection of glucose (2 g/g body weight, D). Blood
was collected from the tail vein, and glucose concentrations were measured at 0, 15, 30, 60, 90, and
120 min. CR signiﬁcantly improved glucose tolerance throughout the IPGTTs, but metformin only sig-
niﬁcantly improved glucose tolerance at 60, 90, and 120 min. Values displayed are means§ SEM of 8
mice per group.***P < 0.001, CR vs. ad libitum-fed ob/ob mice;`P < 0.05,yyP < 0.01, andyyyP < 0.001,
metformin vs. ad libitum-fed ob/ob mice.
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Kit (Fig. 2E). Liver sections were also stained with hematoxylin
and eosin (H&E,£40) to visualize lipid accumulation under all
treatment conditions. Extensive macrovesicular steatosis sur-
rounding the perisinusoidal areas was present in ad libitum-fed
ob/ob mice. However, visible decreases in the accumulation of
intracellular lipid droplets were observed in ob/ob mice upon
treatment with both metformin and CR (Fig. 2F).
Metformin reduces oleic acid-induced lipid accumulation
in hepatocytes in vitro
To confirm the lipid clearance effects of metformin on pri-
mary mouse hepatocytes in vitro, we stained lipid droplets with
Oil Red O (ORO) and quantified them with an ELISA kit
(Fig. 3A); furthermore, we also quantified TGs in HepG2 cells
via spectrophotometry (Fig. 3B). As shown in Figure 3, treat-
ment with 2 mM OA for primary hepatocytes (0.021 §
0.004 vs. 0.028§ 0.002, p < 0.01) and 1 mM OA for HepG2
cells (0.27§ 0.01 vs. 0.36§ 0.005, p < 0.001) significantly
increased intracellular lipid accumulation in the presence of
30 mM glucose for 8 h. However, pretreatment with 0.5 mM
metformin significantly attenuated OA-induced lipid
accumulation in both primary mouse hepatocytes (0.028 §
0.002 vs. 0.022§ 0.004, p < 0.05) and HepG2 cells (0.36§
0.005 vs. 0.29§ 0.01, p < 0.01).
SIRT1 expression and induction of autophagy are
suppressed in type 2 diabetic ob/ob mice, but are ameliorated
by metformin
SIRT1 regulates autophagy by deacetylating autophagy
machinery, including the autophagic players ATG5, ATG7, and
LC3. To test the hypothesis that hepatic SIRT1 expression and
autophagy induction are suppressed in type 2 diabetes, and that
restoration of SIRT1 expression and autophagy induction can be
achieved by treatment with metformin and CR in the ob/ob
mouse model of type 2 diabetes, SIRT1 and autophagy induction
were evaluated in this model. Compared to C57bl/6j mice,
downregulated hepatic expression of SIRT1 protein as well as
mRNA and SIRT1 activity were observed in C57bl/6j back-
ground ob/ob mice, while SIRT1 expression and activity were
restored in ob/ob mice treated with a 4-wk course of CR or met-
formin (Fig. 4A). With respect to autophagy, LC3-I to LC3-II
conversion were significantly increased, while expression of
Figure 2. Hepatic effects of metformin and caloric restriction on ob/ob mice. Serum chemistry values (A-C), as well as TG contents and hepatic histology
(D-F), were evaluated after 4 wk of metformin administration or CR. Levels of T-CHO, as well as GOT1 and GPT activity, were signiﬁcantly decreased in
ob/ob mice treated with metformin or CR compared to ad libitum-fed ob/ob mice (A-C). Mice treated with either metformin or CR also showed a signiﬁ-
cant decrease both in liver weights adjusted by body weights (D) and also in hepatic fat accumulation (E) compared to ad libitum-fed ob/ob mice. Stain-
ing of liver sections with H&E (£ 40) revealed extensive macrovesicular steatosis around the perisinusoidal area in ad libitum-fed ob/ob mice (F). Values
displayed are means§ SEM of 8 mice per group. Asterisks (*P < 0.05,**P < 0.01,***P < 0.001) indicate signiﬁcant differences compared to ad libitum-fed
ob/ob mice.
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SQSTM1 was decreased in ob/ob mice treated with a 4-wk
course of CR or metformin compared to those fed ad libitum
(Fig. 4B).
To verify autophagic flux under the in vivo condition, leupep-
tin was administrated into each mouse before sacrifice and the
rate of LC3-II accumulation after leupeptin injection was calcu-
lated from immunoblots (Fig. 4C). Consistent with in vitro find-
ings, this leupeptin-based assay demonstrated that leupeptin
treatment significantly increased the amount of LC3-II accumu-
lation (designated as LC3 net flux) in ob/ob mice treated with
CR or metformin compared to ad libitum-fed mice.
Furthermore, autophagosomes and autolysosomes were deter-
mined in the liver tissue of each group using an electron micro-
scope to support the evidence of autophagy induction (Fig. 4D).
Hepatocytes in ob/ob mice treated with a 4-wk course of CR or
metformin had a significantly increased number of autophagic
vacuoles compared with those fed ad libitum.
Oleic acid suppresses hepatic expression of SIRT1 and
autophagy induction, but metformin restores SIRT1 expression
and activates the autophagy machinery
To test the possible mechanisms by which a dysfunctional
autophagic pathway results in lipid accumulation, and functional
autophagy mediates lipid clearance, the integrity of the
autophagy machinery was assessed on
several levels. First, we demonstrated
OA-induced suppression of SIRT1 in
both a dose- (0, 0.1, 0.5, 1.0 mM) and
time- (0, 3, 6, 9, 12, 24 h) dependent
manner in both HepG2 cells and pri-
mary hepatocytes (Fig. 5Ai and Aii). Sec-
ond, we employed multiple techniques
to demonstrate OA-induced dysfunc-
tional autophagy in vitro. Dysfunctional
autophagy was first validated with auto-
phagic flux assays; as shown in
Figure 5B, 1.0 mM OA in the presence
of 30 mM glucose suppressed conversion
of LC3-I to LC3-II (designated as LC3
net flux), compared to the control group.
Next, we employed fluorescence confocal
microscopy to visualize autophagosome
formation. HepG2 cells and primary
hepatocytes ectopically expressing GFP-
LC3 exhibited a decrease in the number
of punctate GFP-LC3 structures upon
exposure to 1.0 mM OA, either in the
presence or absence of 50 mM chloro-
quine (CQ; Fig. 5Ci and Cii).
Then, we examined metformin-
induced upregulation of SIRT1 expres-
sion and autophagy induction in vitro.
As shown in Fig. 6A, HepG2 cells and
primary hepatocytes exposed to different
concentrations of metformin (0, 0.1, 0.5,
1.0 mM) showed significantly increased
activity and expression of SIRT1, in a dose-dependent manner.
Metformin also upregulated the expression of phosphorylated
PRKA (pPRKA) and pACAC (phosphorylated acetyl-CoA car-
boxylase) in a dose-dependent manner (Fig. 6A). Consistent with
these findings in vitro, both metformin and CR significantly
induced mRNA expression of the gene encoding ACADM (acyl-
CoA dehydrogenase, C-4 to C-12 straight chain), one of the key
enzymes in the b-oxidation pathway7 in liver tissues compared
with those fed ad libitum (Fig. 6B). In autophagy flux assays,
increased conversion of LC3-I to LC3-II and reduction of
SQSTM1 expression were observed in both metformin-treated
HepG2 cells and primary hepatocytes (Fig. 6C). This increase in
LC3 net flux and decrease in SQSTM1 expression occurred in a
dose-dependent manner. In addition, electron microscopy analy-
sis showed that the numbers of autophagosomes and autolyso-
somes were significantly increased after metformin treatment in
hepatocytes (Fig. 6D).
Furthermore, pretreatment with 0.5 mM metformin pre-
vented OA-induced suppression of SIRT1 expression and LC3-II
conversion (Fig.7A). An autophagic flux assay using CQ showed
that the conversion of LC3-I to LC3-II was blocked in OA-
treated hepatocytes, but was restored after metformin treatment.
In addition, increased expression of SQSTM1 by OA was signifi-
cantly reduced after metformin pretreatment. To test the
Figure 3. Metformin reduces oleic acid-induced lipid accumulation in hepatocytes in vitro. Treat-
ment with OA (2.0 mM for primary hepatocytes, 1.0 mM for HepG2 cells) in combination with
30 mM glucose for 8 h signiﬁcantly increased intracellular lipid accumulation. In contrast, pretreat-
ment with 0.5 mM metformin for 2 h before OA exposure signiﬁcantly reduced OA-induced lipid
accumulation in both primary hepatocytes (A) and HepG2 cells (B), as assessed by visualization and
quantiﬁcation of ORO staining (£ 40). Values displayed are means § SEM of 8 independent experi-
ments. Asterisks (*P< 0.05,**P < 0.01,***P < 0.001) indicate signiﬁcant differences.
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hypothesis that metformin reduces lipid accumulation by induc-
ing autophagy, we inhibited the induction of autophagy with
either siRNA directed against ATG5, or a pharmacological inhib-
itor of autophagy, 3-methyladenine (3MA). Intracellular lipid
accumulation in HepG2 cells and primary mouse hepatocytes
was analyzed by using a spectrophotometer at 520 nm and a col-
orimetric quantification kit, respectively (Fig. 7B–D). While
1.0 mM OA significantly increased the lipid contents of HepG2
cells (0.17§ 0.003 vs. 0.37§ 0.01, P < 0.001), 0.5 mM metfor-
min significantly decreased intracellular fat loading (0.37 §
0.01 vs. 0.34§ 0.01, P< 0.05). However, after siRNA-mediated
knockdown of ATG5, metformin no longer attenuated OA-
induced lipid accumulation (0.39§ 0.01 vs. 0.37§ 0.003, p D
0.15; Fig. 7B). Similarly, metformin was also unable to attenuate
OA-induced lipid accumulation in the presence of 5 mM 3MA
in both HepG2 cells (0.11§0.003 vs. 0.12§ 0.002, p D 0.08;
Fig. 7C) and primary mouse hepatocytes (0.029 § 0.001 vs.
0.03§ 0.001, p D 0.61; Fig. 7D).
Metformin activates SIRT1 expression through a PRKA-
independent pathway
To determine whether metformin induced SIRT1 expression
through a PRKA-independent pathway, siRNAs directed against
PRKAA1/2 or SIRT1 were transfected into HepG2 cells. Metfor-
min upregulated SIRT1 activity as well as its expression, regard-
less of PRKA expression levels (Fig. 8A). With respect to
autophagy, metformin significantly increased the level of LC3-II,
while it decreased SQSTM1 expression in both PRKA-sufficient
and -deficient conditions. In Fig. 8B, metformin treatment sig-
nificantly reduced lipid accumulation in OA-treated HepG2 cells
Figure 4. SIRT1 expression and autophagy induction are decreased in ob/ob mice. Immunoblots, SIRT1 activity assay, and real-time PCR and immunohis-
tochemistry for SIRT1 were performed in mice liver tissues (A). Hepatic expression and activity of SIRT1 and induction of autophagy were signiﬁcantly
decreased in ad libitum-fed ob/ob mice, compared to C57bl/6j control mice. Furthermore, a 4-wk treatment course of either metformin or CR signiﬁ-
cantly restored the expression and activity of SIRT1 and induction of autophagy in ob/ob mice. Expression of LC3 and SQSTM1 was shown as a densito-
metric graph of the optical density-based data of immunoblots (B). LC3 immunoblots were conducted in liver tissues from 4 experimental groups to
analyze autophagy ﬂux in vivo using a leupeptin-based assay (C). Autophagy ﬂux was expressed as the subtraction of the amount of LC3-II in the absence
of leupeptin from the amount of LC3-II in the presence of leupeptin for each of the conditions, which is deﬁned as “LC3 net ﬂux” and graphically dis-
played (C, right graph). Autophagosomes (red arrows) and autolysosomes (white arrows) were shown in the electron microscopy images from ad libi-
tum-fed ob/ob mice and ob/ob mice treated with CR or metformin (D). Scale bars are indicated. The numbers of autophagic vacuoles (autophagosomes
and autolysosomes) per cell (n D 20) were counted and graphically displayed (D, right graph). Values displayed are means§ SEM of at least 5 indepen-
dent experiments. Asterisks (*P< 0.05,**P < 0.01 and***P < 0.001) indicate signiﬁcant differences.
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regardless of the presence of PRKA. Interestingly, the amount of
lipid was much lower in OA and metformin co-treated cells
transfected with control siRNA compared to those with
PRKAA1/2 siRNA (0.337§ 0.01 vs. 0.359§ 0.005, P < 0.05).
After transfection with siRNA against SIRT1, SIRT1 knockdown
did not interfere with metformin-induced phosphorylation of
PRKA (Fig. 8C).
SIRT1 attenuates lipid accumulation in hepatocytes through
SIRT1-mediated autophagy induction
To confirm that SIRT1-mediated autophagy induction was
responsible for hepatic lipid clearance, either a vector driving
SIRT1 overexpression or siRNA directed against SIRT1 were
transfected into HepG2 cells. As shown in Figure 9A and B, the
SIRT1 vector increased SIRT1 expression, decreased SQSTM1
levels and promoted subsequent conversion of LC3-II, whereas
SIRT1 siRNA downregulated SIRT1 expression, increased
SQSTM1 levels and decreased the conversion of LC3-II. OA-
induced lipid accumulation was significantly alleviated by trans-
fecting the SIRT1 vector into both HepG2 cells (0.019 §
0.0007 vs. 0.015§ 0.0005, p < 0.05; Fig. 9C) and primary hep-
atocytes (0.011§ 0.001 vs. 0.008§ 0.0005, p < 0.05; Fig. 9D).
To elucidate whether hepatic lipid clearance required the SIRT1-
mediated autophagy pathway, we disrupted this pathway through
both siRNA knockdown of SIRT1 expression and the pharmaco-
logical inhibitor 3MA. Intracellular lipid accumulation in
HepG2 cells and primary mouse hepatocytes were analyzed using
a spectrophotometer at 520 nm and a colorimetric quantification
kit, respectively. While 2 mM OA significantly increased the
lipid contents in HepG2 cells (0.28§ 0.007 vs. 0.4§ 0.02, p <
0.05), 0.5 mM metformin significantly decreased this intracellu-
lar fat loading (0.4§ 0.02 vs. 0.35§ 0.008, p < 0.05). However,
Figure 5. Oleic acid downregulates hepatic expression of SIRT1 and suppresses autophagy machinery. HepG2 cells and primary hepatocytes exposed to
OA in combination with 30 mM glucose exhibited decreased levels of SIRT1, as assessed by immunoblots, in a dose- (0, 0.1, 0.5 and 1.0 mM OA) and
time- (0, 3, 6, 9, 12, and 24 h) dependent manner (Ai and Aii designated as HepG2 cells and primary hepatocytes, respectively). Furthermore, treatment
with the lysosomal inhibitor CQ (50 mM) in combination with 1.0 mM OA and 30 mM glucose decreased LC3-II conversion, whereas CQ alone upregu-
lated LC3-II levels in LC3 immunoblot ﬂux assays (Bi and Bii). Autophagy ﬂux was expressed as the subtraction of the amount of LC3-II in the absence of
CQ from the amount of LC3-II in the presence of CQ for each of the conditions, which is deﬁned as “LC3 net ﬂux” and graphically displayed. Fluorescence
confocal microscopy was used to monitor the vesicle formation step of autophagy and autophagosome-lysosome fusion in the absence or presence of
50 mM CQ (Ci and Cii). The number of GFP-LC3 puncta was quantiﬁed and plotted. Punctate patterns of the autophagic marker GFP-LC3 were decreased
in response to autophagic inhibition by 1.0 mM OA. Asterisks (**P < 0.01 and***P < 0.001) indicate signiﬁcant differences.
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upon siRNA-mediated SIRT1 knockdown, metformin was
unable to attenuate OA-induced lipid accumulation (0.41 §
0.007 vs. 0.39§ 0.008, pD 0.11) in HepG2 cells (Fig. 9E). Sim-
ilarly, after siRNA-mediated SIRT1 knockdown in primary
mouse hepatocytes, metformin also did not attenuate 1 mM
OA-induced lipid accumulation (0.012 § 0.0008 vs. 0.01 §
0.0007, p D 0.54, Fig. 9F). In the absence of 5 mM 3MA,
1 mM OA-induced lipid accumulation was significantly attenu-
ated by overexpression of SIRT1 (0.017§ 0.0017 vs. 0.012§
0.0006, p < 0.05). However, in the presence of 5 mM 3MA,
OA-induced lipid accumulation was not alleviated by SIRT1
overexpression (0.017§ 0.0013 vs. 0.016§ 0.0011, p D 0.76,
Fig. 9G).
Discussion
Autophagy facilitates the removal of damaged proteins and
aged organelles, thereby maintaining cellular homeostasis. Under
conditions of nutrient deprivation, induction of autophagy pro-
vides a simple response for cells to reutilize their own constituents
for energy.8,9 From a translational point of view, nutritional dep-
rivation through CR causes weight reduction on the individual
level, and induces autophagy on the cellular level. Similar to CR,
metformin causes weight reduction and induces autophagy
through PRKA activation.10,11 Metformin belongs to the bigua-
nide class of drugs and inhibits complex I of the electron trans-
port chain by sequentially lowering the cellular energy charge
Figure 6. Metformin upregulates SIRT1 and stimulates induction of autophagy. Metformin upregulated the expression and activity of SIRT1, phosphory-
lated PRKA (pPRKA), and phosphorylated ACAC (pACAC) in a dose-dependent manner, as shown by immunoblots from HepG2 cells and primary hepato-
cytes (Ai and Aii, respectively). Asterisks (*P < 0.05 and**P < 0.01) indicate signiﬁcant differences compared to the no-metformin control. Real-time RT-
PCR of Acadm (acyl-CoA dehydrogenase, C-4 to C-12 straight chain) expression in mouse livers (B) showed that CR and metformin treatment signiﬁcantly
increased the level of Acadm. In LC3 ﬂux assays, metformin increased LC3-II expression in a dose-dependent manner (0, 0.1, and 0.5 mM), and CQ
(50 mM) upregulated LC3-II conversion in HepG2 cells and primary hepatocytes, as assessed by immunoblots (Ci and Cii). Autophagy ﬂux was expressed
as the subtraction of the amount of LC3-II in the absence of CQ from the amount of LC3-II in the presence of CQ for each of the conditions, which is
deﬁned as “LC3 net ﬂux” and graphically displayed. Expression of SQSTM1 was decreased in metformin-treated cells in a dose-dependent manner, while
it increased after addition of CQ (50 mM). In transmission electron microscopy images (D), the number of autophagosomes (red arrows) and autolyso-
somes (white arrows) were signiﬁcantly increased in primary hepatocytes treated with metformin compared with controls. Scale bars are indicated. The
numbers of autophagic vacuoles (autophagosomes and autolysosomes) per cell (n D 20) were counted and graphically displayed (D, right graph).
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and then activating PRKA.12,13 In this regard, lifestyle modifica-
tion through CR and taking metformin are thought to induce
autophagy; a promising approach for treating NAFLD.8,14 Based
on these reports, we used an animal model to implement CR as a
lifestyle modification, and metformin as a drug therapy in both
cellular and animal models.
The traditional role of PRKA is to act as a cellular stress and
energy sensor, and its activity increases upon glucose depriva-
tion.11 It is also well established that PRKA can cooperate with
the fuel/NADC-dependent sirtuin class of histone/protein deace-
tylases (SIRTs). SIRT1 has been reported to mediate the benefi-
cial metabolic effects of CR through deacetylation of
transcription factors such as PPARG (peroxisome proliferator-
activated receptor gamma), PPARA, PPARGC1A (peroxisome
proliferator-activated receptor gamma, coactivator1 a) and
FOXO (forkhead box O). These transcription factors are
involved in diverse processes such as hepatic lipid metabolism,
gluconeogenesis, mitochondrial biogenesis, and energy expendi-
ture.15-18 Particularly, liver-specific SIRT1 deletion induces
hepatic steatosis and inflammation via impairment of PPARA
signaling.18 Conversely, both PRKA and SIRT1 are downregu-
lated in the liver under stress conditions of nutrient excess,
including a high-fat diet, obesity, and type 2 diabetes.15,19,20 In
addition, SIRT1-deficient mice exhibit a premature aging pheno-
type and develop fatty livers.18,21,22 Based on these reports, we
investigated the molecular interplay between SIRT1, PRKA, and
autophagy in response to metformin.
The present study aimed to determine whether metformin
alleviates hepatosteatosis through SIRT1-mediated autophagy
induction, and whether this mechanism is PRKA-independent.
This work had 3 main findings: First, SIRT1 expression and
induction of autophagy are significantly downregulated both in
Figure 7. Metformin reduced OA-induced lipids by autophagy induction. Metformin also inhibited OA-induced downregulation of SIRT1 expression and
autophagy induction (A). HepG2 cells (Ai) and primary hepatocytes (Aii) exposed to 1.0 mM OA showed a signiﬁcant decrease in SIRT1 expression and
autophagy induction, whereas pretreatment with 0.5 mM metformin signiﬁcantly reduced OA-induced autophagy dysfunction. Expression of indicated
proteins was shown as a densitometric graph of the optical density-based data of immunoblots. Furthermore, LC3 immunoblot ﬂux assays showed that
treatment with the lysosomal inhibitor CQ (50 mM) in combination with 1.0 mM OA alone decreased LC3-II conversion, whereas treatment with 0.5 mM
metformin in the presence of CQ increased LC3-II expression in both HepG2 cells and primary hepatocytes regardless of OA. Autophagy ﬂux was
expressed as the subtraction of the amount of LC3-II in the absence of CQ from the amount of LC3-II in the presence of CQ for each of the conditions,
which is deﬁned as “LC3 net ﬂux” and graphically displayed. Lipid accumulation was determined by fat quantiﬁcation in the presence or absence of the
autophagic inhibitor 3MA, and also after siRNA-mediated knockdown of ATG5. OA-treated primary mouse hepatocytes and HepG2 cells exhibited a sig-
niﬁcant increase in lipid accumulation. However, treatment with 0.5 mM metformin signiﬁcantly decreased the OA-induced intracellular lipid accumula-
tion (B-D). Furthermore, the lipid contents of both HepG2 cells transfected with siRNA against ATG5 (B) and HepG2 cells (C) or primary hepatocytes (D)
treated with 5 mM 3MA in the presence of metformin and OA were similar to those of cells treated with OA alone. Values displayed are means§ SEM of
5 independent experiments. Asterisks (*P < 0.05,**P < 0.01 and***P < 0.001) indicate signiﬁcant differences.
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the livers of ob/ob mice and also in OA- plus 30 mM glucose-
treated hepatic cell lines. Second, both CR and metformin treat-
ment caused weight reduction and alleviated hepatosteatosis and
glucose homeostasis in ob/ob mice in association with increasing
SIRT1 expression and induction of autophagy. Third, metformin
treatment restored SIRT1 expression and, consequently, induc-
tion of autophagy, via a PRKA-independent pathway.
Regarding the effects of metformin on hepatosteatosis, defini-
tive evidence that metformin is the treatment option of choice
for fatty livers in humans is still lacking. Even taking into account
the comorbidities of NAFLD with other diseases such as obesity,
glucose intolerance, and dyslipidemia, the primary cause of lipid
accumulation in the liver is not yet clear. An increased supply of
free fatty acids, de novo hepatogenic lipogenesis, decreased oxida-
tion of free fatty acids, and secretion of hepatic very-low-density
lipoprotein-triglycerides have all been implicated in the develop-
ment of NAFLD.8,23,24 The need to develop a new model of the
molecular pathways responsible for NAFLD has generated
intense interest in autophagy as a pathway that could be manipu-
lated for the management of NAFLD.8,14 Here, we used the ob/
ob mouse model, which mimics type 2 diabetes, to show that
these mice exhibited increased body weight, an accumulation of
hepatic fat, decreased hepatic levels of SIRT1, and suppressed
autophagic machinery when fed ad libitum. However, metformin
treatment of these mice caused significant weight reduction and
alleviated hepatic lipid accumulation. In vitro experiments with
both primary hepatocytes and HepG2 cells were performed with
a monounsaturated fatty acid (OA) in the presence of high glu-
cose, which minimizes inflammatory lipogenic effects. In these
experiments, metformin decreased intracellular fat contents and
Figure 8. Metformin upregulates SIRT1 expression through a PRKA-independent pathway. HepG2 cells were transfected with siRNA against PRKAA1/2 or
a scrambled siRNA control. Densitometric graphs of the optical density-based data of immunoblots (A) showed that SIRT1 expression and activity were
signiﬁcantly upregulated after metformin treatment in HepG2 cells regardless of PRKA expression levels. Metformin also decreased SQSTM1 expression
while it increased LC3-II levels in both control and PRKAA1/2 siRNA-treated cells. Oil Red O staining and spectrophotometer analysis of HepG2 cells trans-
fected with either siRNA against PRKAA1/2 or scrambled siRNA control demonstrated that metformin signiﬁcantly decreased lipid accumulation in cells
treated with OA (B). HepG2 cells were then transfected with siRNA against SIRT1, and a scrambled siRNA control, showing that the ratio of pPRKA and
PRKA expression was increased upon treatment with metformin regardless of SIRT1 levels (C). Values displayed are means§ SEM of 3 to 6 independent
experiments. Asterisks (*P < 0.05,**P < 0.01 and***P < 0.001) indicate signiﬁcant differences.
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activated the autophagy machinery. The activation of the autoph-
agy machinery was demonstrated on several levels, including
examining LC3 turnover in the absence or presence of CQ to
measure the induction of autophagy, and using fluorescence
microscopy to visualize autophagosome formation via GFP-LC3
localization. Most importantly, a leupeptin-based in vivo animal
assay25 was applied to assess the dynamics of autophagic flux
under the in vivo condition, showing that both metformin and
CR induced autophagic flux in the liver of ob/ob mice. However,
considering previous reports showing age-related decline in
autophagy function in livers,26,27 it is quite possible that
metformin may be less able to alleviate hepatic steatosis in elderly
human subjects by activation of autophagy.
Regarding the mechanisms by which CR and metformin
unload caloric burden, the role of PRKA as a key energy sensor
for suppressing lipid accumulation and cell growth is well estab-
lished. In contrast, the MTOR (mechanistic target of rapamycin)
signaling pathway has been proposed to have an opposing role to
PRKA with respect to protein synthesis, cell growth, and cell
division.28 Inhibition of MTOR induces autophagy, a process
which plays a homeostatic role not only by breaking and remov-
ing cellular components, but also by decreasing cellular stores of
Figure 9. SIRT1 attenuates lipid accumulation in hepatocytes through SIRT1-mediated induction of autophagy. Increased protein levels of SIRT1 in
HepG2 cells transfected with a SIRT1 vector increased LC3-II conversion, while decreased expression of SQSTM1 was veriﬁed by immunoblots (A). Expres-
sion ratio of pPRKA/PRKA was also increased in SIRT1 overexpression cells. Furthermore, transfection with siRNA against SIRT1 decreased both SIRT1 pro-
tein levels and also conversion of LC3-I to LC3-II (B). Expression of SQSTM1 was signiﬁcantly increased, while pPRKA levels were not affected. To
investigate whether SIRT1 could regulate lipid accumulation in hepatocytes, either a SIRT1 overexpression vector or siRNA directed against SIRT1 were
transfected into HepG2 cells and primary mouse hepatocytes. In HepG2 cells (C) and primary hepatocytes (D), OA-induced increases in intracellular TG
contents were signiﬁcantly reduced by SIRT1 overexpression. In accordance with the data presented in Figure 6D, OA-induced intracellular lipid accumu-
lation was signiﬁcantly alleviated by metformin treatment of control siRNA-treated HepG2 cells (E) and primary hepatocytes (F). In contrast, reduction of
lipid contents by metformin was negligible in SIRT1-knockdown cells. Lipid accumulation was also examined in the presence or absence of the autopha-
gic inhibitor 3MA (G). OA-treated HepG2 cells exhibited a signiﬁcant increase in lipid accumulation. However, SIRT1 overexpression signiﬁcantly
decreased OA-induced intracellular lipid accumulation. Lipid contents of cells treated with 5 mM 3MA and transfected with SIRT1 were similar to those
of cells treated with OA alone. Values are displayed as means§ SEM of 8 mice per group. Asterisks (*P< 0.05,**P< 0.01,***P< 0.001) indicate signiﬁcant
differences.
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TGs, as demonstrated in this study in hepatocytes. Under low-
nutrient conditions, increased PRKA activity controls the induc-
tion of autophagy by activating either the MTOR-ULK1 or the
SIRT1-FOXO signaling pathway.3,4 In addition, metformin acti-
vates both PRKA and SIRT1 through a PRKA-mediated increase
in gene expression of NAMPT (nicotinamide phosphoribosyl-
transferase), the rate-limiting enzyme of the salvage pathway for
NADC.5 In this study, we tested whether SIRT1 regulates the
autophagic machinery, and whether this regulation required
PRKA activation; to this end, we used siRNA to manipulate cel-
lular levels of both SIRT1 and PRKAA1/2. We observed that
both SIRT1 and pPRKA were still upregulated upon treatment
with metformin even under PRKAA1/2 and SIRT1 knockdown
conditions, respectively. Taken together, we suggest that metfor-
min induces SIRT1 gene expression via a PRKA-independent
pathway, thereby resulting in autophagy induction.
The present study has some limitations, which should be
addressed by further research. Although it is well known that
autophagic activation induces lipophagy, which leads to
decreased cellular lipid content, we did not demonstrate direct
evidence of lipophagy as a link between increased autophagic flux
by metformin and reduced lipid accumulation in hepatocytes.
Moreover, additional experiments with genetically engineered
animal models such as liver-specific Atg7- or Sirt1-knockout
mice should be conducted in the future to provide a more defini-
tive mechanistic role of metformin.
Regarding autophagy-induced clearance of hepatic fat con-
tent, metformin was no longer able to alleviate lipid accumula-
tion either in the presence of an inhibitor of autophagy, 3MA, or
upon siRNA-mediated knockdown of ATG5, an important
player in the elongation step of autophagosome formation. In
addition, overexpression of SIRT1 stimulated induction of
autophagy, thereby alleviating the increase in hepatic fat content
normally caused by OA. Furthermore, the TG-lowering action
of SIRT1 was also abolished by incubation with 3MA. Collec-
tively, these data suggest that metformin-mediated alleviation of
increased hepatic fat content involves the autophagy machinery
(Fig. 10), a finding that may have implications for the pathogen-
esis and treatment of hepatosteatosis.
Materials and Methods
Animal procedures
Eight-wk-old ob/ob mice (C57bl/6j background, Jackson
Laboratory, 000632) and C57bl/6j control mice (Jackson Labo-
ratory, 000664) were used in this study. ob/ob mice were sepa-
rated into 3 groups (n D 8) and subjected to the following
treatment regimens: 1) ad libitum feeding of chow diets (Dyets
Inc..) and vehicle injection of phosphate-buffered saline (PBS,
pH 7.8; GIBCO, 10010); 2) ad libitum feeding of chow diets
and intraperitoneal injections of 300 mg/kg metformin (Merck
KGaA, 317240, n D 8); and 3) CR group (3 g/d, n D 8). Mice
were maintained at 60§ 5% relative humidity and 22§ 2C,
with a 12-h light/dark cycle. Mouse weight and food intake were
measured daily over a 4-wk course of treatment. All experimental
procedures performed in this study followed ethical guidelines
for animal studies, and were approved by the Institutional Ani-
mal Care and Use Committee of Yonsei University College of
Medicine (IACUC No. 2011–0302–1).
Leupeptin assay for measuring autophagic flux
Mice were intraperitoneally injected with sterile PBS or PBS
containing 25 mg/kg leupeptin hemisulfate (Sigma, L2884).
After injection, mice were returned to their cages and provided
water without any food for 5 h.24
Metabolic and biochemical analyses
For IPGTTs, 3-wk-old mice were fasted overnight and given
an intraperitoneal injection of glucose (2 mg/g body weight;
Sigma, G7021). Blood was collected from the tail vein, and glu-
cose concentrations were measured at 0, 15, 30, 60, 90, and
120 min using a handheld glucose meter (SD Code Free, Stan-
dard Diagnostics, Inc., 01GC110). After sacrificing the mice at
4 wk, blood was obtained by cardiac puncture, and mouse livers
were removed and weighed. Serum levels of GOT1/AST (Asan
Pharm Inc., AM101), GPT/ALT (Asan Pharm Inc.., AM101),
and T-CHO were quantified using a commercial kit (Asan
Pharm Inc., AM202).
Histological analysis
After each animal was sacrificed, fresh tissues were immedi-
ately frozen and subsequently placed in prelabeled base molds
filled with embedding medium to ensure optimal cutting temper-
ature. Frozen sections (7 mM) were stained with ORO (Sigma,
O0625); paraffin-embedded sections were stained with H&E
(Dako, CS700, CS701). To evaluate hepatic steatosis, morpho-
metric analysis was performed on 2 randomly selected fields (at
40£ magnification) from a section of each animal using an
Figure 10. Summary of working thesis of the study. See the text for
details.
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Olympus IX71 microscope equipped with an Olympus DP70
camera (Olympus Optical Company, Tokyo, Japan). Immuno-
histochemical analysis for the expression of SIRT1 was conducted
as previously described.29 After epitope retrieval by heat in cit-
rate, deparaffinized sections were incubated with anti-SIRT1
antibody (Santa Cruz Biotechnology, sc-155464)) for 1 h, rinsed
with Tris-buffered saline (Sigma, T5912) containing 0.1%
Tween-20 (Sigma, P1379), and incubated with a secondary anti-
body (Vector Laboratories, Inc., BA-1000). After washing in
PBS, sections were detected with the horseradish peroxidase–con-
jugated anti-biotin labeling solution (Vector Laboratories, Inc.,
PK-6100). Counterstaining was then performed before examina-
tion under a light microscope. The sections were mounted and
dehydrated permanently in nonaqueous mounting medium. The
slides were photographed at 20£ and 40£ magnification) using
an Olympus IX71 microscope equipped with an Olympus DP70
camera.
Real-time PCR
Total RNA was isolated using TRIZOL reagent (Invitrogen,
15596–018) according to the manufacturer’s instructions and
subjected to reverse transcription followed by quantitative real-
time PCRs using SuperScript III First-strand kit (Invitrogen,
18080–051). cDNA from liver from ob/ob mice was used for
real-time PCR with SYBR Green (Takara, RR820) and run on
an StepOnePlusTM (Life technologies, 4376357) to detect rela-
tive mRNA levels. The sequences of the primers used for mouse
samples were: Acadm, forward primer 50-TGA CGG AGC AGC
CAA TGA-30 and reverse primer 50-TCG TCA CCC TTC TTC
TCT GCT T-30; Sirt1, forward primer 5-ACC TCC CAG ACC
CTC AAG-30 and reverse primer 50- TTC CTT CCT TAT
CTG ACA AAG C-30; Sqstm1, forward primer 50- GCT GCC
CTA TAC CCA CAT CT-30 and reverse primer 50- CGC CTT
CT CCG AGA AAC-30; ActBb, forward primer 50- TGG CGC
TTT TGA CTC AGG AT -30 and reverse primer 50- GGG
ATG TTT GCT CCA ACC AA -30. The sequences of the pri-
mers used for HepG2 cells were: SQSTM1, forward primer 50-
CAG GGC TGA AGG AAG CTG C-30 and reverse primer 50-
AAG CCC ATG GAC AGC ATC TG-30; ACTB, forward
primer 50- TCA TGA AGT GTG ACG TTG ACA TCC GT -30
and reverse primer 50- CCT AGA AGC ATT TGC GGT GCA
CGA TG -30. Quantitative analyses were performed using the
DDcycle threshold method and StepOne Software version 2.2.2.
Isolation of primary hepatocytes and cell culture
Primary mouse hepatocytes were prepared according to the
2-step perfusion method as previously described30 with minor
modifications. Livers were digested with Hank’s balanced salt
solution containing 30 mg/mL of Liberase Blendzyme 3 (Roche,
1814176), 5 mM CaCl2 (Sigma, C1016), 0.1 mg/mL DNaseI
(Roche, 10104159001), and 100 mM HEPES (Sigma, H3375)
for 5 min. After centrifugation, pellets were resuspended in
growth medium consisting of DMEM (Welgene, LM001–05)
supplemented with 2.7 mM D-glucose (Sigma, G8270) and
10% fetal bovine serum and subsequently incubated at 37C in
humidified air containing 5% CO2. After determining cell
viability via trypan blue exclusion testing, hepatocytes were
seeded on collagen-coated 6-well plates (SPL, 50050; 5 £ 105/
well) and incubated for 24 h prior to all experiments. HepG2
cells were maintained in Dulbecco’s modified Eagle’s medium
(Welgene, LM001–05) supplemented with 10% fetal bovine
serum and antibiotics. For pharmacological studies, cells were
incubated with either control (5.5 mM) or high-glucose
(30 mM) medium in the presence of 1 mM oleic acid (Sigma,
O3008) after pretreatment with 0.5 mM metformin for 2 h.
Quantification of lipids by Oil Red O staining
and triglyceride assays
Lipid droplets were initially visualized and subsequently quan-
tified by ORO staining. Primary mouse hepatocytes and HepG2
cells were exposed to 2 mM and 1 mM OA, respectively, in the
presence of 30 mM glucose after pretreatment with or without
0.5 mM metformin, followed by fixation with 10% formalin for
1 h. Fixed cells were then stained in prewarmed ORO solution
(Sigma, O0625) for 1 h in a 60C water bath, and red-stained
lipid droplets were subsequently observed with a light micro-
scope. To quantify lipid accumulation, ORO was eluted with
100% isopropanol and the optical densities of the eluates were
measured using a spectrophotometer at 520 nm. TG levels in
liver tissue, primary mouse hepatocytes, and HepG2 cells were
measured with the Triglycerides Quantification Kit (Biovision,
K622) according to the manufacturer’s instructions.
Plasmid transfections and SIRT1 activity assays
The plasmid construct driving overexpression of SIRT1 was
kindly provided by Professor Hyun-seok Kim (Ewha Womans
University, Seoul, Republic of Korea). Transient transfections of
plasmid DNA were performed using Lipofectamine 2000 (Invi-
trogen, 11668–027) according to the manufacturer’s protocol.
To measure cellular SIRT1 activity, nuclear proteins were
extracted from mouse livers, primary hepatocytes, and HepG2
cells using a Nuclear/Cytosol Fractionation Kit (Pierce Biotech-
nology, 78833). SIRT1 activity was quantified with a SIRT1
Fluorometric Assay Kit (Sigma, CS1040) according to the man-
ufacturer’s protocol. Fluorescence intensities were measured with
a microplate fluorometer (excitation wavelength D 360 nm,
emission wavelength D 450 nm).
RNA interference
Primary hepatocytes and HepG2 cells were transfected with
siRNAs targeting ATG5 (Sigma, SASI_Hs01_00173156), SIRT1
(Sigma, SASI_Hs01_00153666), PRKAA1/2 (Santa Cruz Bio-
technology, sc-45312), or a control siRNA (Sigma, SIC001)
using Lipofectamine 2000 (Invitrogen, 11668–027) by following
the manufacturer’s instructions. Cells were incubated for 16 h
with a transfection mixture containing a final siRNA concentra-
tion of 100 pM, and then supplemented with fresh medium.
Immunoblotting and antibodies
Mouse livers, primary hepatocytes, and HepG2 cells were
lysed in PRO-PREPTM protein extraction solution (iNtRON
Biotechnology, 17081), and the protein contents of the resulting
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lysates were measured with the Bradford assay (Bio-Rad, 162–
0115). Equal amounts of proteins were resolved by SDS-PAGE
and electroblotted onto a nitrocellulose membrane (Bio-Rad,
162–0115). Membranes were subsequently probed as indicated
with the following primary antibodies: LC3B (Cell Signaling
Technology, 2275), PRKA (Cell Signaling Technology, 2603),
pPRKA (Cell Signaling Technology, 2535), pACAC (Cell Sig-
naling Technology, 3661), SIRT1 (Santa Cruz Biotechnology,
sc-155464) and GAPDH (Santa Cruz Biotechnology, sc-25778).
Detection of autophagy
To monitor autophagy, levels of conversion of the autophagy
marker protein MAP1LC3/LC3 (microtubule-associated protein
1 light chain 3)-I to LC3-II were measured by immunoblotting.
Detection of autophagosomes was also performed by transfecting
HepG2 cells with a plasmid driving the expression of GFP-LC3
(ORIGINE, RC100021). Transfected cells were fixed with 4%
paraformaldehyde and then observed with a confocal microscope.
Cells were classified as having either a predominantly diffuse
GFP stain, or as having numerous punctate structures represent-
ing autophagosomes. To assay autophagic flux, LC3 processing
either in the presence or absence of 50 mM of the lysosomal alka-
linizing agent, CQ (Sigma, C6628), was assayed by immunoblot-
ting. For detection of autophagosomes using electron
microscopy, liver tissues of ob/ob mice were fixed with 2% glu-
taraldehyde-2% paraformaldehyde buffered with 0.1 M phos-
phate buffer (pH 7.2) overnight at 4C, post-fixed with 1%
osmium tetroxide in a 0.1 M sodium cacodylate buffer (pH 7.4)
for 1 h at room temperature, and were dehydrated with a graded
series of ethanol as previously described.8 The dehydrated tissues
were then embedded in Epon, poly/Bed812 Embedding kit/
DMP-30 (Polysciences, 08792–1). Sectioning for electron
microscopy examination was accomplished with an ultramicro-
tome (Leica, EM UC7), and electron microscopy was performed
with a JEM-1011 transmission electron microscope (JEOL).
Autophagic vacuoles were counted from at least 20 random cells,
averaged, and expressed as the number of autophagic vacuoles
per cell.
Statistical analysis
Statistical analysis was performed using PRISM (GraphPad
Software Inc..). Results are expressed as means§ SE, and statisti-
cal significance was calculated using Student t test. Alternatively,
for comparisons involving more than 2 groups, one-way analysis
of variance (ANOVA) with a post hoc Bonferroni multiple com-
parison test was used to assess the differences between the groups.
Differences in liver weights among 4 mice groups were compared
by using analysis of covariance (ANCOVA) with adjustment for
body weights. Statistical significance was defined as the conven-
tional P value of < 0.05.
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